Thymulin

Thymulin (facteur thymique serique; FTS) is an endogenous zinc-dependent nonapeptide (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) produced exclusively by thymic epithelial cells, identified by Dardenne and Bach in the 1970s as the circulating thymic hormone responsible for promoting T-cell differentiation and maturation in the peripheral immune system. Biological activity of thymulin requires chelation of a zinc ion to form an active complex; the zinc-thymulin complex binds to receptors on immature T-lymphocytes promoting their differentiation, and modulates the neuroendocrine-immune axis through interactions with pituitary hormones, with blood levels of active thymulin declining measurably with age and zinc deficiency.

immune modulation, T-cell maturation, NK cell support, anti-inflammatory.

Research on Thymulin primarily documents effects related to immune modulation and T-cell maturation and NK cell support and anti-inflammatory. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Thymulin, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

16 providers in the directory currently offer Thymulin.

Thymulin is tracked across 1 research vendor on PeptideBase, at about $2.03 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

This review summarizes evidence that thymulin (FTS), a zinc-dependent thymic nonapeptide, regulates intrathymic and extrathymic T cell differentiation, possesses anti-inflammatory and analgesic properties in the brain, and shows promise in adenoviral gene therapy models for sustaining long-term expression without immune destruction of transduced cells.